| scholarly article | Q13442814 |
| P50 | author | Susan J Melhorn | Q96249055 |
| P2093 | author name string | Christian L Roth | |
| Ellen A Schur | |||
| Vidhi Tyagi | |||
| Anne Smeraglio | |||
| P2860 | cites work | Gastrointestinal satiety signals in humans--physiologic roles for GLP-1 and PYY? | Q28250913 |
| The anorectic effect of GLP-1 in rats is nutrient dependent | Q28484398 | ||
| Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system | Q33840311 | ||
| Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance | Q34157515 | ||
| No difference in satiety or in subsequent energy intakes between a beverage and a solid food | Q34343143 | ||
| The biology of incretin hormones | Q34499706 | ||
| Glucagon-like peptide-1: a potent regulator of food intake in humans | Q35565562 | ||
| The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans | Q35700651 | ||
| Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes | Q35772029 | ||
| GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel | Q36249759 | ||
| Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion | Q37061286 | ||
| Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass | Q37100802 | ||
| Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. | Q37110621 | ||
| Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. | Q37136936 | ||
| Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans | Q37377728 | ||
| Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans | Q39801749 | ||
| A simplified, colorimetric micromethod for xylose in serum or urine, with phloroglucinol | Q41675896 | ||
| Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner | Q42134405 | ||
| Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers | Q43638669 | ||
| The effect of acute hyperglycaemia on appetite and food intake in Type 1 diabetes mellitus | Q43770070 | ||
| GLP-1 as a satiety factor in children with eating disorders | Q43969390 | ||
| Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus | Q44467072 | ||
| Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. | Q45271809 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Sustained intracerebroventricular infusion of brain fuels reduces body weight and food intake in rats | Q47283044 | ||
| GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats | Q47442436 | ||
| Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. | Q48218648 | ||
| D-glucose suppression of eating after intra-third ventricle infusion in rat. | Q48398206 | ||
| A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans | Q48664995 | ||
| Time course of effects of preloads high in fat or carbohydrate on food intake and hunger ratings in humans | Q48873625 | ||
| Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men. | Q53039133 | ||
| The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity | Q58448710 | ||
| Limitations of indirect methods of estimating small bowel transit in man | Q70344615 | ||
| Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects | Q71128936 | ||
| Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies | Q73510748 | ||
| Stimulation of the small intestine by nutrients in relation to phase of the migrating motor complex | Q73927840 | ||
| Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans | Q74081998 | ||
| The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction | Q74287135 | ||
| Effects of hyperglycemia and hyperinsulinemia on satiety in humans | Q74310151 | ||
| Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39 | Q77804907 | ||
| Effects of a preload on reduction of food intake by GLP-1 in healthy subjects | Q79394103 | ||
| P921 | main subject | satiety | Q1562684 |
| P304 | page(s) | 85-90 | |
| P577 | publication date | 2014-07-15 | |
| P1433 | published in | Appetite | Q13430275 |
| P1476 | title | Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans | |
| P478 | volume | 82 |
| Q36240979 | Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes |
| Q39047697 | Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. |
| Q42936904 | Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight |
| Q33838133 | Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure |
| Q38575560 | Intestinal GLP-1 and satiation: from man to rodents and back |
| Q53589377 | Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. |
Search more.